Nurix Therapeutics, Inc. NRIX 深 滬
等待開盤 01-29 09:30:00 美东时间
17.93
-1.480
-7.62%
華盛通- 最 高19.575
- 今 開19.44
- 成交量 49.69万股
- 最 低 17.93
- 昨 收 19.41
- 總市值 18.11亿
- 52周最高 22.4999
- 市盈率 靜 --
- 換手率 0.49%
- 52周最低 8.18
- 委 比 24.08%
- 總股本 1.01亿
- 歷史最高 52.38
- 量 比 0.56
- 振 幅 8.48%
- 歷史最低 4.22
- 每 手 1
- 風險率 3.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Upgrades Nurix Therapeutics to Overweight, Raises Price Target to $36
Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight to Overweight and raises the price target from $15 to $36.
01-08 20:10
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics, Inc. announced that its CEO, Arthur T. Sands, M.D., Ph.D., will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. The presentation will be available via webcast on the company's website. Nurix, focused on targeted protein degradation medicines for oncology and autoimmune diseases, has a clinical-stage pipeline including BTK degraders and CBL-B inhibitors, as ...
01-05 12:00
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Wells Fargo Maintains Overweight on Nurix Therapeutics, Raises Price Target to $30
Wells Fargo analyst Derek Archila maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $21 to $30.
2025-12-16 22:59
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
美股牛股 | “减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%
“减肥神药”临床数据引爆！WaVe生命科学涨超147%，硕迪生物涨超102%；Confluent涨超29%，IBM拟110亿美元收购该公司>>
2025-12-09 17:40
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
